Cardiovascular Health

A new Nature Communications study led by researchers at the University of Bristol and University College London reports that GLP‑1 medications — the class that includes Ozempic‑style weight‑loss and diabetes drugs — may protect heart tissue from a dangerous complication called 'no‑reflow' after a heart attack, at least in animal models. The team describes a brain–gut–heart signaling pathway in which GLP‑1 triggers nerve signals that open specific potassium channels in pericytes, tiny cells that help control capillary diameter, allowing narrowed microvessels in the heart to relax and improve blood flow after a blocked artery is cleared. Lead author Dr. Svetlana Mastitskaya notes that nearly half of heart‑attack patients experience this microvascular 'no‑reflow,' which is linked to higher one‑year risks of heart failure and death. The experiments showed that when the relevant potassium channels were removed, GLP‑1 drugs no longer conferred protection, suggesting the mechanism is necessary for the benefit. While the authors say the findings raise the possibility of repurposing existing GLP‑1 drugs as emergency treatments during or immediately after heart attacks, they stress that the work so far is in animals, not people, and that clinical trials are needed to confirm whether the same pathway operates with similar timing and strength in humans or offers any longer‑term protective effect.